Caplin Point Laboratories has informed that the meeting of the Board of Directors of the Company is scheduled on 11/01/2019 to consider and approve the Business Transfer Agreement to be entered into with its Wholly Owned Subsidiary Company, Caplin Steriles, for transfer of business undertaking of the Company (Regulated Markets Injectable Business, including US FDA approved Injectable Plant and DSIR recognized R&D Units CP4 and CP5), besides considering other allied subjects pursuant to the approval granted by the members of the Company through Postal Ballot.
The above information is a part of company’s filings submitted to BSE.
